Abstract
The development of new angiogenic inhibitors highlights a need for robust
screening assays that adequately capture the complexity of vessel formation,
and allow for the quantitative evaluation of the teratogenicity of new antiangiogenic
agents. This review discusses the use of screening assays in vertebrate embryos, specifically focusing upon chicken and zebrafish embryos, for the detection of anti-angiogenic agents.
screening assays that adequately capture the complexity of vessel formation,
and allow for the quantitative evaluation of the teratogenicity of new antiangiogenic
agents. This review discusses the use of screening assays in vertebrate embryos, specifically focusing upon chicken and zebrafish embryos, for the detection of anti-angiogenic agents.
Original language | English |
---|---|
Pages (from-to) | 49-59 |
Number of pages | 10 |
Journal | Reproductive Toxicology |
Volume | 70 |
Early online date | 22 Nov 2016 |
DOIs | |
Publication status | Published - 1 Jun 2017 |
Bibliographical note
Shaunna Beedie is a recipient of a Wellcome Trust-NIH PhD Studentship (Grant number 098252/Z/12/Z). Alexandra J. Diamond is a recipient of a BBSRC EastBIO DTP PhD Scholarship. Lucas Rosa Fraga is a recepient of a PhD scholarship from the Science Without Borders program – CNPq Brazil – INAGEMP/ Grant CNPq 573993/2008-4 Shaunna Beedie and William D. Figg are supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government.Keywords
- angiogenesis
- chicken
- zebrafish
- mouse
- rat
- rabbit
- non-human primates
- thalidomide